A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

ID#: NCT04513925

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: Phase 3

Recruitment Status: Recruiting

Start Date: August 30, 2020

End Date: December 30, 2027

Contact Information:
GO41854 www.roche.com/about_roche/roche_worldwide.html
888-662-6728 (U.S. Only)
Summary: The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
Eligibility:

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

- Histologically or cytologically documented NSCLC with locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology

- Whole-body Positron Emission Tomography-Computed Tomography (PET-CT) scan, performed prior and within 42 days of the first dose of concurrent chemoradiotherapy (CRT)

- At least two prior cycles of platinum-based chemotherapy concurrent with radiotherapy (cCRT), which must be completed within 1 to 42 days prior to randomization in the study

- The radiotherapy (RT) component in the cCRT must have been at a total dose of radiation of 60 (±10 percent [%]) gray (Gy) (54 Gy to 66 Gy) administered by intensity modulated RT (preferred) or 3D-conforming technique

- No progression during or following concurrent platinum-based CRT

- Tumor PD-L1 expression

- Life expectancy >/= 12 weeks

- Adequate hematologic and end-organ function

- Female participants must be willing to avoid pregnancy for 90 days after the final dose of tiragolumab and 5 months after the final dose of atezolizumab, or for 3 months after the final dose of durvalumab

- Male participants must remain abstinent or use a condom during the treatment period and for 90 days after the final dose of tiragolumab

- Male participants must not donate sperm during the treatment period and for 90 days after the final dose of tiragolumab

Exclusion Criteria:

- Any history of prior NSCLC

- NSCLC known to have a mutation in the epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) fusion oncogene

- Any evidence of Stage IV disease

- Treatment with sequential CRT for locally advanced NSCLC

- Participants with locally advanced NSCLC who have progressed during or after the definitive concurrent CRT prior to randomization

- Any Grade >2 unresolved toxicity from previous CRT

- Grade >= 2 pneumonitis from prior CRT

- Active or history of autoimmune disease or immune deficiency

- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis or evidence of active pneumonitis

- History of malignancy other than NSCLC within 5 years prior to screening

- Prior allogeneic stem cell or solid organ transplantation

- Active Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection at screening

- Treatment with investigational therapy within 28 days prior to initiation of study treatment

- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T lymphocyte-associated protein 4, anti-T-cell immunoreceptor with Ig and ITIM domains (anti-TIGIT), anti-PD-1 and anti-PD-L1

- Any prior Grade >/= 3 immune-mediated adverse event or any unresolved Grade > 1 immune-mediated adverse event while receiving any previous immunotherapy agent other than immune checkpoint blockade agents

- Treatment with systemic immunosuppressive medication

- Women who are pregnant, or breastfeeding